MedTrace Logo

Fermented Dairy Product and Bifidobacterium Diversity (ThreeBees)

NCT06799364 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 182

Last updated 2026-04-21

No results posted yet for this study

Summary

Bifidobacterium strains with potential health benefits can contribute to the gastrointestinal wellbeing. However, the ability of these strains to survive gastro-intestinal tract stress and their impact on gut microbiome remains to be clarified. Moreover, prebiotic fibres, such as galacto-oligosaccharides (GOS) can promote the proliferation of Bifidobacteria. This is why the current study aims to assess the impact of Bifidobacteria consumption on human gut microbiome with or without GOS compared to control product.

Conditions

  • A03 - Digestive System
  • B03 - Bacteria

Interventions

OTHER

28-days consumption of Product A in 45 to 60-year-old healthy subjects.

48 healthy volunteers will consume Product A twice per day during 28 consecutive days.

OTHER

28-days consumption of Product B in 45 to 60-year-old healthy subjects.

48 healthy volunteers will consume Product B twice per day during 28 consecutive days.

OTHER

28-days consumption of Control product in 45 to 60-year-old healthy subjects.

48 healthy volunteers will consume Control product twice per day during 28 consecutive days.

Sponsors & Collaborators

  • Danone Global Research & Innovation Center

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-21
Primary Completion
2025-12-22
Completion
2026-04-15

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06799364 on ClinicalTrials.gov